The Chopra Foundation and MindMed Enter Into Letter of Intent to Partner on the Future of Psychedelic Medicines & Mental WellbeingPRNewsWire • 05/18/21
MindMed Stock Moves Higher After Finalizing Generalized Anxiety Disorder As Initial Indication For LSD TrialBenzinga • 05/17/21
MindMed Receives FDA Type C Meeting Response for Project Lucy Phase 2b Clinical TrialPRNewsWire • 05/17/21
MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD ($194m CAD) to Execute on Diverse Clinical PipelinePRNewsWire • 05/14/21
EXCLUSIVE: MindMed CEO Talks Mission To 'Discover, Develop And Deploy' PsychedelicsBenzinga • 05/13/21
MindMed Bolsters Management Team, Appoints Peter Mack PhD as Vice President of Pharmaceutical DevelopmentPRNewsWire • 05/13/21
MindMed Announces Project Angie, Targeting the Treatment of Pain with PsychedelicsPRNewsWire • 05/05/21
MindMed's Nasdaq Listing Enables Institutions Diversified Access To A New Age Of MedicineBenzinga • 04/30/21
MNMD Stock: A MindMed Buzz Kill as the Psychedelic Shares Tank on First Day of TradingInvestorPlace • 04/27/21
MindMed Stock Climbs In Nasdaq Debut As Psychedelics Follow Pot's Path To MainstreamInvestors Business Daily • 04/27/21